Galectin Therapeutics Inc. (NASDAQ:GALT) Stock Holdings Lifted by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC lifted its holdings in Galectin Therapeutics Inc. (NASDAQ:GALT) by 46.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 51,510 shares of the company’s stock after buying an additional 16,412 shares during the quarter. Wealth Enhancement Advisory Services LLC owned approximately 0.08% of Galectin Therapeutics worth $66,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of GALT. LPL Financial LLC increased its holdings in shares of Galectin Therapeutics by 69.6% in the 4th quarter. LPL Financial LLC now owns 138,928 shares of the company’s stock worth $179,000 after acquiring an additional 57,020 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Galectin Therapeutics by 94.9% in the 4th quarter. JPMorgan Chase & Co. now owns 59,693 shares of the company’s stock worth $77,000 after acquiring an additional 29,065 shares during the period. Two Sigma Securities LLC acquired a new position in Galectin Therapeutics during the 4th quarter valued at about $37,000. Barclays PLC increased its stake in Galectin Therapeutics by 91.1% during the 4th quarter. Barclays PLC now owns 54,634 shares of the company’s stock valued at $71,000 after buying an additional 26,047 shares during the period. Finally, HighTower Advisors LLC acquired a new position in Galectin Therapeutics during the 4th quarter valued at about $29,000. Institutional investors and hedge funds own 11.68% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright assumed coverage on shares of Galectin Therapeutics in a research note on Tuesday. They set a “buy” rating and a $6.00 target price on the stock.

Galectin Therapeutics Trading Up 37.7%

Galectin Therapeutics stock opened at $3.29 on Thursday. The stock has a market cap of $208.22 million, a price-to-earnings ratio of -4.57 and a beta of 0.54. The company’s 50-day moving average price is $1.39 and its two-hundred day moving average price is $1.44. Galectin Therapeutics Inc. has a 52 week low of $0.73 and a 52 week high of $3.30.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Thursday, May 15th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.05. Research analysts expect that Galectin Therapeutics Inc. will post -0.73 earnings per share for the current fiscal year.

Galectin Therapeutics Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.